- Home
- CABA vs NA Comparison
CABA vs NA Comparison
Compare CABA & NA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- NA
- Stock Information
- Founded
- CABA 2017
- NA 2019
- Country
- CABA United States
- NA China
- Employees
- CABA N/A
- NA N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- NA Semiconductors
- Sector
- CABA Health Care
- NA Technology
- Exchange
- CABA Nasdaq
- NA Nasdaq
- Market Cap
- CABA 118.8M
- NA 109.1M
- IPO Year
- CABA 2019
- NA 2022
- Fundamental
- Price
- CABA $2.06
- NA $6.58
- Analyst Decision
- CABA Strong Buy
- NA
- Analyst Count
- CABA 8
- NA 0
- Target Price
- CABA $26.13
- NA N/A
- AVG Volume (30 Days)
- CABA 1.4M
- NA 66.9K
- Earning Date
- CABA 03-20-2025
- NA 03-17-2025
- Dividend Yield
- CABA N/A
- NA N/A
- EPS Growth
- CABA N/A
- NA N/A
- EPS
- CABA N/A
- NA N/A
- Revenue
- CABA N/A
- NA $6,991,446.00
- Revenue This Year
- CABA N/A
- NA N/A
- Revenue Next Year
- CABA N/A
- NA N/A
- P/E Ratio
- CABA N/A
- NA N/A
- Revenue Growth
- CABA N/A
- NA N/A
- 52 Week Low
- CABA $1.76
- NA $2.75
- 52 Week High
- CABA $24.85
- NA $23.50
- Technical
- Relative Strength Index (RSI)
- CABA 38.28
- NA 44.56
- Support Level
- CABA $2.03
- NA $6.30
- Resistance Level
- CABA $2.90
- NA $7.24
- Average True Range (ATR)
- CABA 0.24
- NA 0.50
- MACD
- CABA -0.04
- NA 0.02
- Stochastic Oscillator
- CABA 4.00
- NA 41.96
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.